MTOR and ovarian carcinoma: This minireview focuses on the recent research reporting the use of inhibitors of the mechanistic/mammalian target of rapamycin (mTOR) and the eukaryotic translation initiation factor 4E (eIF4E) as adjuvants in cancer treatment; despite the limited number of studies performed on ovarian cancer cell models, the encouraging results obtained in vitro and in pre-clinical studies with some inhibitors might establish the use in ovarian cancer therapy.